REGENERON - Diversified Pipeline can Buffer the Setback
Despite the setback in the pipeline – negative recommendation from FDA advisory committee on approval of ARCALYST (R, for prevention of gout flares, PDUFA: July 30, 2012), EYLEA (VEGF Trap-Eye, L in US, partnered with Bayer for Ex-US, wet AMD) remains the key driver for REGN and growth of this franchise should be able to buffer some setbacks in the pipeline. The FDA advisory panel voted 11-0 against approval of the ARCALYST, citing inadequate safety data. REGN’s ex-US partner for Eylea, Bayer entered into co-promotion collaboration with Santen pharma for EYLEA in … For more detail, please read our report, released on May 14, 2012 on REGN, titled “Diversified Pipeline can Buffer the Setback”.
COMPANIES MENTIONED
Regenerion
Regenerion
